Resveravine (Vitis vinifera)

Resveravine is a proprietary Vitis vinifera (grape vine) extract standardized for stilbene compounds, including resveratrol and related polyphenols, which are theorized to support cardiovascular health through antioxidant and anti-inflammatory mechanisms. However, no human clinical trials have been conducted specifically on the Resveravine extract itself, meaning its efficacy and optimal dosage in humans remain unestablished.

Origin & History

Resveravine is a branded proprietary extract derived from grapevine (Vitis vinifera) stems and branches, standardized for stilbenes like resveratrol (11-50%) and ε-viniferin (10-12%). The extract is produced through maceration of ground stems in acetone or ethanol for 12-20 hours, followed by filtration, evaporation, and purification with water/ethanol mixtures.

Historical & Cultural Context

No traditional medicine use is documented for Resveravine or grapevine stem extracts in the available sources. While resveratrol occurs naturally in grape skins and seeds during wine production, stems and branches lack referenced traditional applications in systems like Ayurveda or Traditional Chinese Medicine.

Health Benefits

• No clinical evidence available - potential cardiovascular benefits based only on general resveratrol research, not this specific extract
• No human trials conducted - antioxidant properties theorized from stilbene content but unproven for Resveravine
• No RCTs identified - anti-inflammatory effects possible via NF-κB pathways but lacking clinical validation
• No meta-analyses found - SIRT1 activation potential based on resveratrol mechanism, not studied for this extract
• No safety data established - drug interaction risks with anticoagulants like warfarin via CYP enzyme inhibition remain theoretical

How It Works

Resveravine's proposed mechanisms are extrapolated from resveratrol research, where the stilbene compound activates SIRT1 (sirtuin-1) deacetylase and AMP-activated protein kinase (AMPK), pathways linked to cellular energy regulation and endothelial function. Resveratrol-class stilbenes also inhibit cyclooxygenase (COX-1 and COX-2) enzymes and suppress NF-κB signaling, which may reduce pro-inflammatory cytokine production including TNF-α and IL-6. Additionally, these compounds are theorized to upregulate endothelial nitric oxide synthase (eNOS), potentially improving vasodilation, though none of these pathways have been confirmed specifically for the Resveravine formulation in human tissue.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for Resveravine or equivalent Vitis vinifera stem extracts standardized for resveratrol/ε-viniferin. Available research focuses solely on extraction optimization methods without any clinical efficacy or safety data.

Clinical Summary

No randomized controlled trials, observational studies, or human pharmacokinetic studies have been published specifically investigating the Resveravine extract. Existing cardiovascular evidence is borrowed from broader resveratrol research, including small RCTs (typically 20–100 participants) examining isolated trans-resveratrol at doses of 150–1000 mg/day, which have shown modest reductions in systolic blood pressure and LDL oxidation in some studies. The bioavailability and stilbene profile of Resveravine may differ from isolated resveratrol, making direct extrapolation scientifically unreliable. Until dedicated clinical trials are conducted, any cardiovascular benefit claims for Resveravine specifically remain speculative.

Nutritional Profile

Resveravine is a proprietary or specialized extract derived from Vitis vinifera (grapevine), typically sourced from vine shoots, canes, or root tissues rather than fruit or seeds. It is not a conventional nutritional supplement and lacks a standard macronutrient profile (negligible protein, fat, carbohydrate, and fiber content as it is consumed as a concentrated extract, not a whole food). Key bioactive compounds include: • trans-Resveratrol (3,5,4'-trihydroxystilbene): the principal stilbenoid, typically standardized in vine-derived extracts to approximately 5–20% by weight depending on extraction method and plant part; bioavailability is notably low (<1–5% of oral dose reaches systemic circulation unchanged) due to rapid Phase II metabolism (glucuronidation and sulfation in intestinal epithelium and liver). • Viniferin (ε-viniferin and δ-viniferin): resveratrol dimers/oligomers present in Vitis vinifera woody tissues at variable concentrations (estimated 0.5–5% of extract); ε-viniferin may have greater metabolic stability than resveratrol monomer but human pharmacokinetic data are essentially absent. • Piceatannol (3,3',4,5'-tetrahydroxystilbene): a hydroxylated resveratrol analog found at lower concentrations (~0.1–2%); it is also a metabolite of resveratrol via CYP1B1; may exhibit marginally better absorption than resveratrol in some preclinical models. • Additional stilbenoid oligomers (e.g., hopeaphenol, miyabenol C, ampelopsin A): trace to minor concentrations depending on source tissue (vine shoots vs. roots); biological significance in humans is unknown. • Polyphenolic matrix compounds: minor amounts of catechins, epicatechins, procyanidins, and phenolic acids (gallic acid, caffeic acid) may co-extract but at much lower levels than in grape seed or skin extracts. • Micronutrients: no significant vitamin or mineral content expected from a concentrated stilbene extract; any mineral content (potassium, calcium, magnesium) would be negligible per serving dose. • Typical serving/dose: not standardized; experimental or commercial doses of vine-shoot stilbene extracts range from 100–500 mg of total extract per day, delivering roughly 10–100 mg of combined stilbenoids. • Bioavailability notes: The stilbene backbone undergoes extensive first-pass metabolism; plasma half-life of free resveratrol is approximately 1–3 hours. Conjugated metabolites (resveratrol-3-O-sulfate, resveratrol-3-O-glucuronide) predominate in circulation and may retain partial biological activity, though this remains debated. Co-administration with dietary fats or piperine has been suggested to modestly enhance absorption in preclinical studies but is unvalidated for Resveravine specifically. The oligomeric stilbenoids (viniferins) have higher molecular weight and potentially different absorption kinetics, but no human pharmacokinetic studies exist for these compounds from this specific extract source.

Preparation & Dosage

No clinically studied dosages exist for Resveravine. Analytical yields show standardized extracts contain 11-28% resveratrol and 10-12% ε-viniferin, but these are not therapeutic dose recommendations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Grape Seed Extract, Pine Bark Extract, Green Tea Extract, Turmeric

Safety & Interactions

Because no dedicated human safety trials exist for Resveravine, its side effect profile is inferred from resveratrol studies, where gastrointestinal symptoms such as nausea, diarrhea, and abdominal discomfort have been reported at doses above 1000 mg/day. Resveratrol-class stilbenes may inhibit CYP3A4 and CYP2C9 liver enzymes, raising the risk of interactions with anticoagulants such as warfarin, antiplatelet drugs like aspirin or clopidogrel, and certain statins. Due to weak estrogenic activity at the ER-β receptor, Resveravine should be used with caution by individuals with hormone-sensitive conditions. Pregnant and breastfeeding women should avoid this supplement entirely given the complete absence of safety data for this specific extract in those populations.